A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis - Related Studies

A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis

This study has been terminated.

Study NCT00035529. Last updated on July 24, 2008. Information provided by Bristol-Myers Squibb

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Multiple Sclerosis

2	Additional conditions recognized in this trial
		Multiple Sclerosis, Relapsing-Remitting
		Sclerosis

3	More general conditions related to this trial
		Autoimmune Diseases
		Autoimmune Diseases of the Nervous System
		Demyelinating Autoimmune Diseases, CNS
		Demyelinating Diseases
		Immune System Diseases
		Nervous System Diseases
		Pathologic Processes

4	Interventions listed in this trial
		Placebo
		BMS 188667 (Abatacept)

5	Additional drug interventions recognized in this trial
		Abatacept

6	More general drug interventions related to this trial
		Antirheumatic Agents
		Immunologic Factors
		Immunosuppressive Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Bristol-Myers Squibb